The trading price of Astrazeneca plc ADR (NASDAQ:AZN) closed higher on current market day and closing at $63.80, 0.65% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $63.3053 and $64.13. The company’s P/E ratio in the trailing 12-month period was 30.66, while its 5Y monthly beta was 0.18. In examining the 52-week price action we see that the stock hit a 52-week high of $87.68 and a 52-week low of $60.47. Over the past month, the stock has lost -17.61% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Astrazeneca plc ADR, whose market valuation is $197.82 billion at the time of this writing, is expected to release its quarterly earnings report in December. The dividend yield on the company stock is 2.33%, while its Forward Dividend ratio is 1.49. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest AZN has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned AZN a recommendation rating is 10. Out of them, 2 rate it a Hold, while 8 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Astrazeneca plc ADR (AZN) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 2.55, which symbolizes a positive outlook. A quick review shows that AZN’s price is currently -7.27% off the SMA20 and -14.17% off the SMA50. The RSI metric on the 14-day chart is currently showing 23.28, and weekly volatility stands at 1.45%. When measured over the past 30 days, the indicator reaches 1.82%. Astrazeneca plc ADR (NASDAQ:AZN)’s beta value is currently sitting at 0.47, while the Average True Range indicator is currently displaying 1.52. With analysts defining $79-$88 as the low and high price targets, we arrive at a consensus price target of $85 for the trailing 12-month period. The current price is about -23.82% off the estimated low and -37.93% off the forecast high, based on this estimate. Investors will be thrilled if AZN’s share price rises to $85, which is the median consensus price. At that level, AZN’s share price would be -33.23% below current price.
To see how Astrazeneca plc ADR stock has been performing in comparison to its peers in the industry, here are the numbers: AZN stock’s performance was 0.65% in the latest trading, and -0.51% in the past year. Astrazeneca plc ADR has a P/E ratio of 30.66.
An evaluation of the daily trading volume of Astrazeneca plc ADR (NASDAQ:AZN) indicates that the 3-month average is 5.12 million. However, this figure has increased over the past 10 days to an average of 10.91.
Currently, records show that 3.10 billion of the company’s shares remain outstanding. The insiders hold 0.03% of outstanding shares, whereas institutions hold 15.80%. The stats also highlight that short interest as of 2024-10-31, stood at 4.03 million shares, resulting in a short ratio of 1.3 at that time. It is noteworthy that short shares in October were down slightly from the previous month’s figure, which was 5.39 million. However, since the stock’s price has seen -5.27% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
